Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial protein hyperacetylation in the failing heart
Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly
Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly
View: Text | PDF
Research Article Cardiology Metabolism

Mitochondrial protein hyperacetylation in the failing heart

  • Text
  • PDF
Abstract

Myocardial fuel and energy metabolic derangements contribute to the pathogenesis of heart failure. Recent evidence implicates posttranslational mechanisms in the energy metabolic disturbances that contribute to the pathogenesis of heart failure. We hypothesized that accumulation of metabolite intermediates of fuel oxidation pathways drives posttranslational modifications of mitochondrial proteins during the development of heart failure. Myocardial acetylproteomics demonstrated extensive mitochondrial protein lysine hyperacetylation in the early stages of heart failure in well-defined mouse models and the in end-stage failing human heart. To determine the functional impact of increased mitochondrial protein acetylation, we focused on succinate dehydrogenase A (SDHA), a critical component of both the tricarboxylic acid (TCA) cycle and respiratory complex II. An acetyl-mimetic mutation targeting an SDHA lysine residue shown to be hyperacetylated in the failing human heart reduced catalytic function and reduced complex II–driven respiration. These results identify alterations in mitochondrial acetyl-CoA homeostasis as a potential driver of the development of energy metabolic derangements that contribute to heart failure.

Authors

Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly

×

Figure 1

Increased lysine acetylation of mitochondrial proteins involved in multiple mitochondrial energy transduction pathways in cardiac tissue of mice from the heart failure group.

Options: View larger image (or click on image) Download as PowerPoint
Increased lysine acetylation of mitochondrial proteins involved in multi...
(A) Lysine-acetylated proteins (indicated by circles, protein symbols are noted) identified by mass spectrometry in both heart failure (HF) samples and sham-operated control samples (n = 2/group) in each of the 3 main mitochondrial fuel oxidation/ATP synthesis pathways (β-oxidation, tricarboxylic acid [TCA] cycle, and electron transport complex [ETC]). All acetylated residues with at least ± 1.5 fold change for mean HF/control values are shown. Specific lysine acetylation sites are noted in parentheses. Acetylation status is indicated by color coding: proteins with increased acetylation (HF/sham) are in red; proteins with decreased acetylation are in blue; and proteins with no change are in gray. (B) All detected acetylated mitochondrial proteins were rank ordered according to log2 fold change between compensated hypertrophy (CH) or HF and their corresponding sham controls in mean protein abundance along the x axis (blue circles). The log2 fold change between CH or HF and corresponding sham controls of each detected acetyl isoform (red squares, normalized to corresponding protein abundance) is plotted on the y axis in the same position on the x axis as the corresponding protein. The dashed line represents no change in acetylation level. Additional numerical data is provided in Supplemental Tables 2-4. SDHA, succinate dehydrogenase A.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts